Ravulizumab for relapse prevention in AQP4-IgG–positive neuromyelitis optica spectrum disorder: a 2-year follow-up case report

BackgroundNeuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system, distinct from multiple sclerosis, characterized by severe inflammatory attacks targeting the optic nerves, spinal cord, and brainstem. Treatment has evolved from broad immunosuppressa...

Cijeli opis

Bibliografski detalji

Glavni autori:	Nabil Akkawi, Elkhansa Hassabo Mohamed, Ahmed Shatila
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-06-01
Serija:	Frontiers in Medicine
Teme:	aquaporin-4 complement C5 inhibitor disease-modifying treatment neuromyelitis optica ravulizumab
Online pristup:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1827687/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!